Vertex Pharmaceuticals (VRTX) Gets a Buy from J.P. Morgan
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
South Boston Online1d
Important New VERTEX Painkiller Is Approved
By Rick Winterson  Vertex Pharmaceuticals is a worldwide biotechnology corporation. It was founded 35 years ago in Cambridge.  It has now established its global headquarters on Fan Pier in South ...
pharmaphorum1d
Will 2025 be the year the pharmaceutical industry finds its feet?
Evaluate’s latest analysis forecasts an $82 billion increase in major product revenues in 2025 – the largest annual growth ...
Record-high vacancies aren't stopping construction of new office buildings
The Boston area began 2025 with a record-high office vacancy rate of 17%. Yet there are at least seven notable office ...
BioPharma Dive1d
Vertex challenger Sionna prices $191M IPO
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Zacks.com on MSN3d
Unlocking Q4 Potential of Vertex (VRTX): Exploring Wall Street Estimates for Key Metrics
The upcoming report from Vertex Pharmaceuticals (VRTX) is expected to reveal quarterly earnings of $3.99 per share, indicating a decline of 5% compared to the year-ago period. Analysts forecast ...
FDA approves first new non-opioid painkiller in decades, and it's from a MA company.
The U.S. Food and Drug Administration has approved a new non-opioid pain medication developed by Boston-based Vertex ...
pharmaphorum4d
Algiax non-opioid drug works in chronic neuropathic pain
The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...
Evercore ISI Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) on January 31 and set a price ...